The high prevalence of MDR
S. pneumoniae (58.3%) in Bandar Abbas presents a serious public health challenge, comparable to resistance rates reported in parts of Southeast Asia (30% - 60%) and sub-Saharan Africa (~ 50%) (
5,
6). However, resistance rates for specific antibiotics vary significantly across regions. The observed penicillin resistance rate (41.7%) in Bandar Abbas is substantially higher than the 10% - 15% reported in Europe but aligns with findings from Tehran (43%) and Pakistan (38% - 45%) (
8,
11). This suggests regional differences in antibiotic prescribing patterns and vaccine coverage. Similarly, ceftriaxone resistance (20.8%) in Bandar Abbas is notably higher than in Tehran (8% - 12%) and Pakistan (1%), indicating potential overuse of cephalosporins (
8,
9). Macrolide resistance (azithromycin 45.8%, clindamycin 58.3%) is consistent with reports from India (50% - 60%) but exceeds resistance rates in Saudi Arabia (~ 30%) and Oman (~ 25%) (
7). These findings highlight the need for antimicrobial stewardship programs to regulate antibiotic use and mitigate resistance.
Several key factors were significantly associated with increased resistance in this study. Recent antibiotic use (aOR: 4.5, P < 0.001), daycare attendance (aOR: 2.9, P = 0.004), and household smoke exposure (aOR: 2.4, P = 0.029), align with studies from India and Nigeria that have linked empirical antibiotic therapy to the emergence of MDR pneumococcal strains (
6,
12). The widespread availability of over-the-counter antibiotics and incomplete treatment courses in Bandar Abbas likely exacerbate resistance. Strengthening antibiotic stewardship programs and enforcing stricter regulations on antibiotic sales could help curb this issue.
Children under five years old had a 3.2-fold higher likelihood of carrying resistant
S. pneumoniae strains, consistent with studies from Brazil and South Africa (
13,
14). This is likely due to their developing immune systems and increased exposure in daycare or preschool environments. In this study, daycare attendance was associated with nearly a threefold increase in resistance, underscoring the role of close-contact settings in bacterial transmission and antimicrobial selection pressure. Household smoke exposure significantly increased the risk of resistance (aOR: 2.4, P = 0.048), likely due to smoke-induced mucosal damage that facilitates bacterial colonization (
15). Similar findings have been reported in other studies, emphasizing the need for public health initiatives to reduce indoor smoke exposure.
A particularly concerning finding was the low pneumococcal conjugate vaccine (PCV10) coverage (24.9%), far below the World Health Organization’s recommended 90% coverage. While vaccination status was not significantly associated with resistance (P = 0.089), inadequate vaccine uptake may contribute to the persistence of non-vaccine serotypes that are often resistant to antibiotics (
8,
11). Expanding vaccine coverage is crucial for reducing pneumococcal carriage, transmission, and ultimately antibiotic resistance.
The resistance patterns observed in Bandar Abbas align with global trends but also reveal concerning regional variations. Ceftriaxone resistance (20.8%) was significantly higher than that reported in Tehran (8% - 12%) and Pakistan (1%), suggesting excessive cephalosporin use (
8,
9). A study from the UAE (2010 - 2021) reported increasing resistance to levofloxacin, moxifloxacin, erythromycin, and trimethoprim/sulfamethoxazole (
16). Similarly, in Oman, 56.8% of isolates were non-susceptible to at least one antibiotic, with 40.9% resistant to penicillin and 18.9% classified as multidrug-resistant (
17). These findings emphasize the urgent need for targeted antimicrobial stewardship programs to optimize prescribing practices and limit resistance.
Addressing the increasing burden of MDR S. pneumoniae in Bandar Abbas requires a multifaceted approach:
- Strengthening antibiotic stewardship programs: Implementing evidence-based guidelines for antibiotic prescribing, promoting appropriate use, and restricting over-the-counter antibiotic sales are essential to curb resistance.
- Expanding pneumococcal vaccination coverage: Increasing PCV uptake could significantly reduce pneumococcal colonization and transmission, thereby lowering antibiotic resistance rates.
- Reducing household smoke exposure: Household smoke exposure significantly increased the risk of resistance (aOR: 2.4, P = 0.048), likely due to smoke-induced mucosal damage that facilitates bacterial colonization (
15). Similar findings have been reported in other studies, emphasizing the need for public health initiatives to reduce indoor smoke exposure, particularly in households with young children or individuals with chronic respiratory conditions (
18,
19).
- Enhancing surveillance systems: Robust surveillance programs should be established to monitor emerging resistance patterns, guide empirical treatment decisions, and inform vaccination policies.
- Molecular analysis of resistance mechanisms: Future research should incorporate whole-genome sequencing to track resistance gene evolution and assess the impact of PCV13 on serotype distribution.
5.1. Conclusions
This study highlights the alarming prevalence of MDR S. pneumoniae in Bandar Abbas and underscores the urgent need for targeted interventions. High resistance rates to penicillin, ceftriaxone, and macrolides, combined with low pneumococcal vaccination coverage and risk factors such as recent antibiotic use, young age, and household smoke exposure, present significant challenges for infection control. A collaborative effort between clinicians, policymakers, and public health authorities is essential to implement effective antimicrobial stewardship, expand vaccination programs, and enhance surveillance systems to combat the rising threat of pneumococcal resistance.
5.2. Limitations
- Single-center design: Findings may not be generalizable to other regions in Iran or globally due to localized data collection.
- Lack of molecular analysis: Absence of serotyping and resistance gene profiling (e.g., ermB, mefA) limits insights into resistance mechanisms and vaccine-serotype coverage.
- Small sample size of isolates: Only 48 isolates were analyzed, reducing statistical power and potentially missing significant associations.
- Cross-sectional design: Cannot establish causality between risk factors and resistance, only associations.
- Self-reported data: Risk of recall bias (e.g., antibiotic use) and underreporting (e.g., household smoke exposure).
- Low carriage rate (12.3%): Lower than global averages, possibly influenced by seasonal or demographic factors, raising questions about representativeness.
- Short study duration (3 months): Seasonal variations in pneumococcal carriage and antibiotic use were not accounted for.
- Vaccination coverage gaps: Low PCV10 uptake (24.9%) and lack of association with resistance may reflect confounding factors or insufficient data. Despite low PCV10 coverage, resistance rates were marginally lower in vaccinated children (52.6% MDR) compared to unvaccinated (60.2% MDR), though not statistically significant (P = 0.22).
5.3. Recommendations
- Expand surveillance systems: Implement multi-center, longitudinal studies across diverse regions to improve generalizability. Integrate molecular techniques (e.g., whole-genome sequencing) to track resistance genes and serotype distribution.
- Strengthen antimicrobial stewardship: Enforce stricter regulations on over-the-counter antibiotic sales. Educate healthcare providers on evidence-based prescribing and the public on antibiotic misuse risks.
- Boost vaccination coverage: Prioritize pneumococcal conjugate vaccine (PCV13) introduction and achieve WHO-recommended coverage (> 90%). Conduct serotype surveillance to align vaccination strategies with circulating strains.
- Public health interventions: Launch campaigns to reduce household smoke exposure (e.g., smoking cessation programs). Promote infection control measures in daycare/school settings to limit transmission.
- Policy and collaboration: Align national policies with global antimicrobial resistance (AMR) action plans (e.g., WHO’s global action plan). Foster partnerships between clinicians, policymakers, and international agencies to address AMR holistically.
5.4. Future Research
- Conduct longitudinal studies to assess temporal trends in resistance and vaccine impact.
- Investigate socioeconomic and cultural drivers of antibiotic misuse in the region.
- Future studies should incorporate serotyping and resistance gene profiling to inform vaccine strategies and resistance mechanisms.
- Multi-center collaboration: Larger, multi-center studies would enhance generalizability and statistical power.